WillItSurvive
Pharma and healthcare groups · United States

Moderna

modernatx.com ↗

Moderna makes mRNA vaccines and therapeutics using lipid nanoparticle delivery tech.

Losing its protection
Assessed 24 July 2026 · Evidence as of 24 July 2026
The structural protection is eroding.
On the recordSince 24 July 2026 · Checkable from August 5, 2026 · Every call on the record Checkpoint: FDA PDUFA decision on mRNA-1010 flu vaccine
The call

Moderna holds real vaccine technology and approvals but is shrinking toward a 2028 breakeven target while US policy fights and Pfizer/BioNTech competition play out.

Moderna invented and manufactures mRNA vaccines, a real technology that earned regulatory approvals and government contracts that take years to copy. Right now the company is losing money and facing two big rivals: Pfizer and BioNTech make the same type of vaccine and already have bigger market share, while U.S. vaccine skepticism under new leadership is actively shrinking demand. The picture changes if two things happen in the next year and a half: the company wins its court battles to keep vaccines in the U.S. market, and its new flu shot and cancer vaccine candidates get approved by the FDA, proving the technology works beyond COVID.

Why
01
AI pressure: None apparent. AI speeds Moderna's own vaccine design and manufacturing rather than threatening the business from outside. Could AI do the core job? Unlikely.
02
Bigger players: Pfizer/BioNTech. Pfizer/BioNTech run a coequal mRNA vaccine platform already on the market and hold a larger share of that market. Could a giant copy it? No, they are blocked.
03
What protects it. Approved mRNA/LNP products, manufacturing know-how, government contracts, and a settled global LNP patent license.
What would change this call
FDA PDUFA decision on mRNA-1010 flu vaccine around August 5, 2026. Shows whether Moderna can diversify revenue beyond COVID vaccines.
Outcome of AAP et al. vs. HHS vaccine policy litigation within 6-12 months. Shows whether US domestic vaccine demand stabilizes or keeps shrinking.
Intismeran melanoma Phase 3 interim analysis readout in 2026. Shows whether oncology pipeline can offset declining vaccine revenue.
Key numbers
  • 2025 revenue fell to ~$1.9B from $19.3B in 2022 (2026-02-13)
  • Market cap ~$23.0B, down from $497 ATH in 2021 (2026-07-24)
  • Cash and investments ~$8.1B at end of 2025 (2026-01-12)
Named risks
  • US vaccine policy litigation (RFK Jr HHS actions) could permanently reduce domestic demand. Severity: high
  • Revenue down ~90% from 2022 peak with breakeven not targeted until 2028. Severity: high
  • $950 million settlement payment due Q3 2026 strains cash position. Severity: medium
  • Further unplanned layoffs could signal breakeven plan slipping. Severity: medium
Rivals, as read in July 2026
RivalDirectionEvidence
Pfizer/BioNTechlosing toHolds larger mRNA vaccine market share than Moderna as of mid 2026; ongoing patent litigation reported 2026-04-02
GSK/Sanofigaining onLarge incumbent vaccine makers entering mRNA/adjuvant licensing deals, reported 2026-05-20
NovavaxcontestingProtein-based rival now partnering with Sanofi and licensing to Pfizer rather than competing solo, 2026-06-12
Questions people ask
Is Moderna profitable in 2026?
No. Moderna posted a GAAP net loss of $1.3 billion in Q1 2026, largely from an $878 million litigation charge tied to its Arbutus settlement; underlying loss was about $500 million. Management targets breakeven by 2028, not before, per its May 1, 2026 earnings report.
Did Moderna lay off employees?
Yes. On July 31, 2025, Moderna announced roughly a 10% global workforce cut, affecting 500 to 800-plus employees, aiming for under 5,000 staff by year end 2025 as part of a plan to cut $1.5 to 1.7 billion in annual costs by 2027.
Who is Moderna's biggest competitor?
Pfizer, partnered with BioNTech, is Moderna's chief rival in mRNA vaccines and holds a larger share of the global mRNA vaccine market as of mid 2026. The two companies are also locked in ongoing cross patent litigation over lipid nanoparticle technology, reported April 2, 2026.
Could AI replace Moderna's scientists?
Unlikely to replace core lab science. Moderna instead uses AI internally, deploying over 750 internal AI tools by 2026, with CEO Stephane Bancel saying the company could bring 15 new products to market in five years with a few thousand employees instead of 100,000, per a May 12, 2026 report.
Who owns Moderna?
Moderna is a standalone public company on Nasdaq under ticker MRNA, with no parent company. Market capitalization was approximately $23.0 billion as of July 24, 2026, down sharply from an all time high of $497.49 per share reached in 2021.
Timeline
  • 2026-07-17Details emerge on $2.25B Arbutus/Genevant settlement, $950M due Q3 2026
  • 2026-06-18FDA advisory committee votes 9-0 in favor of flu vaccine mRNA-1010
  • 2026-05-01Q1 2026 results: revenue $389M, up 260% YoY, GAAP loss $1.3B
  • 2026-03-17Federal judge blocks parts of RFK Jr. vaccine policy changes
  • 2026-03-03Moderna settles all worldwide patent litigation with Arbutus/Genevant
  • 2026-02-13FY2025 results reported: revenue fell to ~$1.9B
  • 2026-01-12JPMorgan Healthcare update: $8.1B cash, $0.6B drawn on loan facility
  • 2026-01CDC memo strips seven vaccines, including COVID and flu, of universal recommendation
  • 2025-07-31Moderna announces ~10% workforce layoff and cost-cutting plan
Revision history
24 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
Community Health SystemsViatrisAccendra Health
More in Pharma and healthcare groups →
Sources